Drugs / Picankibart
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07295509 | Dec 2025 → Dec 2029 expected | psoriatic arthritis | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06945107 | May 2025 → Jun 2026 overdue | psoriasis | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Active not recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07552454 | Apr 2026 → Oct 2027 expected | palmoplantar pustulosis | Xijing Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Picankibart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07552454 ↗ |
| Known as | IBI112 | “This is a multicenter, randomized, double-blind, placebo-controlled Phase II/III clinical trial evaluating the efficacy and safety of picankibart (IBI112) in patients with...” NCT07295509 ↗ |
| Modality | Monoclonal antibody | — CHEMBL5314763 ↗ |
| Route | Subcutaneous | “receive picankibart 200mg SC” NCT06945107 ↗ |